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Yttrium-90Abstract Background: For patients with metastatic pancreatic adenocarcinoma, there are no
approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated
radioimmunotherapy was undertaken in this setting, administering 90Y-clivatuzumab tetrax-
etan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma
mucin) with or without low radiosensitising doses of gemcitabine.
Methods: Fifty-eight patients with three (2–7) median prior treatments were treated on Arm A
(N = 29, 90Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m2 doses  3, plus gemcitabine, weekly
200 mg/m2 doses  4 starting 1 week earlier) or Arm B (N = 29, 90Y-clivatuzumab tetraxetan
alone, weekly 6.5 mCi/m2 doses  3), repeating cycles after 4-week delays. Safety was the
primary endpoint; efﬁcacy was also evaluated.
Results: Cytopaenias (predominantly transient thrombocytopenia) were the only signiﬁcant
toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed P1 full
treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including
seven (6 Arm A, 1 Arm B; 12%) given 3–9 cycles. Two patients in Arm A had partial responses
by RECIST criteria. Kaplan–Meier overall survival (OS) appeared improved in Arm A versus
B (hazard ratio [HR] 0.55, 95% CI: 0.29–0.86; P = 0.017, log-rank) and the median OS for
Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32,
P = 0.004), including three patients in Arm A surviving >1 year.
Conclusions: Clinical studies of 90Y-clivatuzumab tetraxetan combined with low-dose
gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a
Phase III trial of this combination is now underway in this setting.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The outlook for patients with advanced pancreatic
adenocarcinoma remains poor [1]. In the frontline, med-
ian survival was 6.2–6.7 months with gemcitabine alone
[2] or with erlotinib [3], 8.5 months combined with
albumin-bound paclitaxel (Abraxane) [4] and
11.1 months for those able to tolerate combination
chemotherapy (FOLFIRINOX) [5]. Beyond the 1st line,
the survival advantage with chemotherapy remains lim-
ited [6–8], and after two prior treatments (one usually
gemcitabine-based, the other ﬂuoropyrimidine-based),
there are no accepted treatments [9–11]. We instead
pursued radioimmunotherapy to target and directly irra-
diate tumour sites without needing to physically over-
come transport barriers in pancreatic cancer (high
interstitial pressure, dense stromal reaction) or be incor-
porated into the tumour cells to be eﬀective [12].
PAM4, an anti-MUC5ac monoclonal antibody
selectively binding to pancreatic adenocarcinoma mucin
[13–16], proved active when radiolabeled in preclinical
models of human pancreatic cancer [17,18]. After
humanisation and conjugation with DOTA (1,4,7,10-te
traazacyclododecane-N,N0,N00,N000-tetraacetic acid), the
chelate-conjugate (clivatuzumab tetraxetan) was labeled
with 90-yttrium (90Y), a beta-emitting radionuclide witha radiation path-length of 5 mm suitable for bulky
tumours. 90Y-clivatuzumab tetraxetan was initially
administered as a single dose [19], but fractionated doses
should be more eﬀective [20]. Gemcitabine is a known
radiosensitiser [21], tolerated clinically at low doses with
external radiotherapy [22], and preclinical studies
showed enhanced anti-tumour activity combining
90Y-labeled PAM4 with gemcitabine [23–25]. In the
frontline, fractionated doses of 90Y-clivatuzumab tetrax-
etan combined with 200 mg/m2 doses of gemcitabine
achieved 7.7 months median overall survival in patients
with Stage III or IV disease, but 11.8 months for those
patients given repeated treatment cycles; manageable
myelosuppression was the principal side-eﬀect [26].
After receiving two prior treatments, there
is an unmet medical need for further therapy.
Radioimmunotherapy may be particularly attractive
for patients considering continued treatment, but unable
or unwilling to tolerate the side eﬀects of further
chemotherapy. As such, this Phase Ib study was under-
taken to determine if our approach, which had previ-
ously been used in the frontline setting, would be safe
in such an advanced population. Secondarily, we
wanted to further examine the role of low-dose gemc-
itabine in the treatment regimen before pursuing a large
deﬁnitive trial.
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This was an open-label, multicenter phase Ib study of
90Y-clivatuzumab tetraxetan administered with or with-
out 200 mg/m2 gemcitabine in patients with metastatic
pancreatic adenocarcinoma after P2 prior therapies.
Primary study objectives included evaluating treatment
safety and tolerability in this setting. Additional
objectives were to obtain evidence of eﬃcacy based on
survival, CT imaging and CA19-9 serum levels, assess
the contribution of gemcitabine to this treatment regi-
men and evaluate any immunogenicity towards this
antibody-based regimen. Institutional review boards at
each site approved the study. Written informed consent
was obtained from all patients.2.1. Population
AdultsP18 years old with metastatic pancreatic ade-
nocarcinoma must have received P2 prior chemother-
apy regimens for their advanced disease and have
measureable disease by CT imaging, but no CNS
metastases or bulky disease (no single massP 10 cm).
Other requirements included Karnofsky performance
statusP 70%, haemoglobinP 9 g/dL, neutrophils
[ANC]P 1500/mm3, plateletsP 100,000/mm3, crea-
tinine and bilirubin 6 1.5 IULN (institutional upper
limit of normal), AST and ALT 6 2.0 IULN, with
any prior external radiation therapy <2000 cGy to lungs
and kidneys, <3000 cGy to liver, <30% of red marrow,
and with 6Grade 2 nausea/vomiting, anorexia or signs
of intestinal obstruction.2.2. Treatment and assessments
Immunomedics, Inc., (Morris Plains, NJ) provided
clivatuzumab tetraxetan in 10 mg kits to local commer-
cial radiopharmacies for 90Y-radiolabeling. The prior
study in treatment of naı¨ve patients found that patients
at the 6.5 or 9.0 mCi/m2 dose levels had adequate plate-
let and neutrophils levels to initiate a second cycle with-
out the need for dose reduction or delay [26,27]. Since
patients in this study likely have decreased bone marrow
reserve after two or more prior chemotherapy regimens,
the lower dose of 6.5 mCi/m2 was selected for this pop-
ulation, with 90Y-clivatuzumab tetraxetan administered
in the hospital nuclear medicine department by slow
injection over 5–10 min without steroids of other
premedication. Commercially available gemcitabine pre-
pared by the hospital pharmacy was given intravenously
over 30 min.
Patients were alternately assigned to treatment arms
by the Sponsor, who was not informed of prior history
other than meeting eligibility. In Arm A, patients
received 6.5 mCi/m2 Y-clivatuzumab tetraxetan
once-weekly for 3 weeks together with 200 mg/m2gemcitabine once-weekly for 4 weeks starting 5 days
before beginning 90Y-clivatuzumab tetraxetan and then
2 days after each dose. In Arm B, patients received only
6.5 mCi/m2 Y-clivatuzumab tetraxetan once-weekly for
3 weeks. For both arms, treatment cycles were repeated
after 4 weeks following the last dose until unacceptable
toxicity, progressive disease or patient withdrawal. The
full 90Y-clivatuzumab tetraxetan dose was administered
for ANCP 1000/mm3 and plateletsP 100,000/mm3;
otherwise, a 75% dose for ANCP 750/mm3 and
plateletsP 75,000/mm3, or a 50% dose for lower values
with ANCP 500/mm3 and plateletsP 50,000/mm3,
with the dose held if ANC < 500/mm3 or
platelets < 50,000/mm3 and treatment delayed on a
weekly basis until blood levels permitted dosing to con-
tinue. Gemcitabine doses were held if 90Y-clivatuzumab
tetraxetan doses were held, but were otherwise given
without reduction.
Adverse events were graded by NCI-CTCAE v4.0
[28]. Vital signs, physical examination, blood counts,
serum chemistries and CA19–9 serum levels were evalu-
ated during treatment cycles, then 4, 8 and 12 weeks
after the last cycle. Serum samples were evaluated by
enzyme immunoassay for any human anti-hPAM4 anti-
bodies (HAHA). CT scans were obtained at least every
7–8 weeks from treatment initiation until progression
and interpreted by local radiologists. Tumour lesion
changes were categorised as a complete response (CR),
partial response (PR), stable (SD) or progressive disease
(PD) by RECIST v1.0 [29], and with disease control
deﬁned as achieving PR or CR or else SD for at least
8 weeks from treatment initiation. 18F-FDG-PET or
PET/CT imaging was optional. All patients were fol-
lowed for survival.2.3. Statistical analysis
The primary endpoint was analysed by frequency of
adverse events and toxicities, including cytopaenias.
Overall survival (OS) from ﬁrst dose to death or last con-
tact was analysed by Kaplan–Meier methods, while
additional endpoints were summarised by descriptive
statistics. An active therapy in this population would
be assumed to have a disease control rate ofP25% ver-
sus 5% for an inactive therapy. Using a SWOG two-stage
programme [30] results in a sample size ofP25 patients
per treatment arm and guards against futility by termi-
nating accrual on an arm at interim assessment if none
of the ﬁrst 15 patients achieve disease control.3. Results
3.1. Patients and study treatment
Fifty-eight patients with a median of 3 (range, 2–7)
prior chemotherapy regimens were treated in Arm A
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2013. All had received gemcitabine-containing regimens
(21% with nab-paclitaxel) while 97% had received
ﬂuoropyrimidine-containing regimens (50% with
FOLFIRINOX). Table 1 summarises patient demo-
graphics and baseline characteristics for each arm.
No drug-related interruptions, discontinuations or
adverse reactions occurred with treatment administra-
tions. Five patients rapidly deteriorated before ﬁnishing
one cycle (stroke, entered hospice, biliary obstruction,
pulmonary embolism and severe constipation).
Patients terminated further treatment due to
disease progression/clinical deterioration or other
treatment-unrelated events, with 30/58 (52%) patients
(15 per arm) completing only one cycle and 23 (40%)
patients (12 Arm A, 11 Arm B) receiving multiple cycles,
including 16 (6 Arm A, 10 Arm B) given two cycles and
seven (6 Arm A, 1 Arm B) given 3–9 cycles. For cycle 1,
8/58 (14%) patients hadP1 doses of 90Y- clivatuzumab
tetraxetan reduced to 75%; but, besides the ﬁve patients
who rapidly deteriorated, no doses were held. For
repeated cycles, 16/23 (70%) patients had P1 doseTable 1
Demographics and baseline characteristics.
Arm A Arm B
Patients, N 29 29
Sex, M/F 19/10 14/15
Age, median (range) 62 (39–73) 66 (51–80)
Karnofsky performance status, N
90–100 14 10
70–80 15 19
Haematology, median (range)
Platelets (1000/lL) 211 (100–577) 224 (113–570)
Neutrophils (1000/lL) 5.2 (1.9–15.1) 5.4 (3.0–13.4)
Haemoglobin (g/dL) 11.3 (9.2–
15.1)
11.6 (9.4–15.8)
Years from diagnosis, median
(range)
1.8 (0.3–4.1) 1.5 (0.4–3.7)
Stage IV disease, N (%) 29 (100%) 29 (100%)
Extent of disease, median (range)
CA19-9 (U/mL) 863 (0.8–
ULa)
2720 (6.5–
ULa)
Sum of index lesions (cm) 9.8 (1.7–19.0) 7.1 (1.2–22.2)
Tumour location, N (%)
Pancreas, including resection bed 11(38%) 15 (52%)
Liver 14 (48%) 17 (59%)
Other abdomen sites 13 (45%) 16 (55%)
Lung 13 (45%) 12 (41%)
Prior therapies
Pancreatectomy, N (%) 15 (52%) 9 (31%)
External radiation, N (%) 10 (34%) 8 (28%)
Chemotherapy regimens
Median (range) 3 (2–7) 3 (2–6)
Most frequent, N (%)
Gemcitabine-containing 29 (100%) 29 (100%)
Gemcitabine/nab-paclitaxel 6 (21%) 6 (21%)
Fluoropyrimidine-containing 28 (97%) 28 (97%)
FOLFIRINOXb 17 (59%) 12 (41%)
a UL = upper limit of quantitation, nominally >200,000 U/mL.
b Irinotecan, oxaliplatin and 5-ﬂuorouracil/leucovorin combination.reduced to 75% (N = 7) or 50% (N = 9), including 11
(48%) who also had P1 dose held.3.2. Adverse events
Events considered at least possibly treatment-related
were thrombocytopenia, 50% of patients; fatigue, 26%;
anaemia, 22%; nausea, 16%; leukopaenia, neutropenia,
12% each; abdominal pain, anorexia, vomiting, diar-
rhoea, 9% each; bleeding, fever, chills, 7% each; dysp-
noea, hyperbilirubinemia, headache, 5% each and
others <5%. These included GradeP3 events of throm-
bocytopenia, 19%; anaemia, leukopaenia and neutrope-
nia, 7% each ; others 62%.
Comparison of events regardless of assumed treat-
ment relationship shows limited diﬀerences between
treatment arms, and AEs occurring more frequently
(>10% diﬀerence) in arm A (fatigue, neutropenia,
leukopaenia, nausea, diarrhoea, dyspnoea, alkaline
phosphatase, headache) or arm B (ascites, asthenia, gas-
trointestinal pain or tenderness) were primarily limited
to Grade 1–2 events (Table 2).
Six patients (three per arm) had serious events con-
sidered at least possibly treatment-related. Two patients
had cerebrovascular accidents (stroke), one occurring
after only one dose and the other one month after cycle
1. One patient developed disseminated intravascular
coagulopathy after cycle 2 with Grade 4 thrombocy-
topenia, acute renal failure and fatal gastrointestinal
haemorrhage. Another developed consumptive coagu-
lopathy with Grade 4 thrombocytopenia after cycle 1
recovering within one week and workup revealing lower
extremity deep venous thrombosis and sub-acute cere-
bral infarcts. One patient developed fever after cycle 3
with negative cultures but responded to antibiotics,
while another patient with a history of severe infections
developed fatal Gram-negative bacteremia during cycle
2; both had undergone recent biliary stent placements
and were not neutropenic at time of event.
Overall, 20/58 (34%) patients (10 per arm) developed
Grade >3 thrombocytopenia (four given platelets), 14
(11 Arm A, 3 Arm B; 24% overall) developed Grade
P3 neutropenia (four given cytokine support) and 11
(7 Arm A, 4 Arm B; 19% overall) developed Grade >3
anaemia (eight transfused). In patients with follow-up
data, only four events (all thrombocytopenia) remained
at Grade 4 levels >7 days, while all Grade 3 cytopaenias
recovered to Grade 2 levels within 12 weeks. Grade P3
cytopaenias generally increased with repeated cycles but
Grade 4 occurrences generally remaining limited
(Table 3).
Infections occurred in 11 (19%) patients, including
four serious events [fatal septic entercolitis from
pre-study pancreatectomy (Sump syndrome); fatal septic
bacteremia from unidentiﬁed source; post-interventional
Grade 3 acute cholangitis; Grade 3 pneumonia
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[upper respiratory infection (URI)  4, urinary tract
infection (UTI)  3, superﬁcial fungal infection  2,
pneumonia, Lyme disease). The fatal bacteremia was
considered possibly-related although the patient had a
history of severe infections and recent biliary stent place-
ment; other infections were considered unrelated by the
investigators. Furthermore, only three patients were
neutropenic (700–900 cells/lL) at time of infection
(pneumonia, UTI, URI).
Bleeding occurred in nine (16%) patients, including
three serious events (fatal GI bleeding from consumptive
coagulopathy, Grade 3 melena from concomitant medi-
cations, Grade 3 GI bleeding from underlying disease)
and seven minor Grade 1 events (bruising  4, epistaxis,
haemorrhoids, conjunctival). Minor bruising was con-
sidered at least possibly study drug related, but the other
bleeding events were all considered unrelated by the
investigators, and only three patients had Grade 3–4Table 2
Frequent adverse events regardless of attribution.a
Patients with adverse event Arm A
All Grades (%)
Laboratories
Thrombocytopenia 62
Anaemia 45
Neutropenia 28
Leukopaenia 24
Alkaline phosphatase 24
Hyponatraemia 21
Aspartate aminotransferase 17
Lymphopaenia 14
Hyperbilirubinemia 14
Hyperglycaemia 14
Hypoalbuminaemia 14
Clinical events
Fatigue 76
Nausea 41
Anorexia 31
Abdominal/gastrointestinal pain or tenderness 31
Constipation 28
Diarrhoea 28
Dyspnoea 28
Infection 24
Vomiting 21
Abdominal distension 17
Bleeding 17
Back pain 17
Cough 17
Dehydration 14
Headache 14
Hypertension 14
Fever 14
Pleural eﬀusion 10
Peripheral oedema 10
Ascites 0
Asthenia 0
a
Events occurring in >10% of the 29 patients in either treatment arm.thrombocytopenia at time of event (consumptive coagu-
lopathy, bruising  2).
3.3. Eﬃcacy
The median overall survival (OS) for all 58 patients
was 2.7 months, with all patients now deceased.
Kaplan–Meier survival curves (Fig. 1) showed improve-
ment in Arm A versus B beginning at about 3 months,
with the relative number of patients remaining alive in
Arm A versus B then progressively increasing with time
(hazard ratio [HR] 0.55, 95% CI: 0.29–0.86; P = 0.017,
log-rank test). Median OS for Arm A versus B
(Table 4) was only 2.7 versus 2.6 months overall, but
increased to 7.9 versus 3.4 months for those patients
who received multiple cycles (HR 0.32, P = 0.004),
including three patients in Arm A surviving >1 year
(one for 1.5 years, two for 2.0 years). OS generally
increased with better performance status and lowerArm B
Grade P3 (%) All Grades (%) Grade P3 (%)
21 52 17
14 38 10
10 3 3
14 3 3
3 10 0
7 14 7
0 7 7
10 17 10
3 21 3
3 14 7
0 3 3
3 38 7
0 24 3
0 24 7
3 48 10
0 28 3
0 10 0
7 14 0
7 17 7
3 28 3
0 7 0
3 14 7
7 14 0
0 7 0
3 17 3
0 0 0
7 3 0
0 14 0
7 17 7
0 14 0
0 14 3
0 14 3
Table 3
Grade 3 and 4 haematological toxicity by treatment cycle.
Cycle N Thrombocytopenia Neutropenia Anaemia
Grade 3
N (%)
Grade 4
N (%)
Grade 3
N (%)
Grade 4
N (%)
Grade 3
N (%)
Grade 4
N (%)
1 58 4 (7) 6 (10) 10 (17) 1 (2) 5 (9) 0 (0)
2 23 7 (30) 2 (9) 3 (13) 0 (0) 4 (17) 0 (0)
3–9 7 3 (43) 2 (29) 1 (14) 1 (14) 3 (43) 0 (0)
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degree with fewer prior therapies and smaller tumour
burden estimated by summing lengths of index lesions
(Table 4).
There was >25% disease control (PR + SD) in both
treatment arms at interim evaluation, thus meeting the
SWOG two-stage criteria to complete enrolment. By
RECIST criteria, there were two PRs (both Arm A)
and 22 SDs (10 Arm A, 12 Arm B) as best response, with
other patients having progressed by ﬁrst CT evaluation
4 weeks after cycle 1. Median OS for those with PR, SD
and PD was 11.5, 5.1 and 1.8 months, respectively.
Eleven patients had elevated CA19-9 levels at baseline
that decreased with treatment, either 20–50% and
considered a minor response (N = 8), or >50% and
considered an objective response (N = 3). Median OS
for patients with CA19-9 responses was 3.9 versus
2.5 months for the remaining population.3.4. Immunogenicity
Five patients (1 arm A, 4 arm B) with baseline serum
samples that were HAHA-negative (<50 ng/mL) becameFig. 1. Overall survival. Kaplan–Meier curves and time-point analyses
over 12 months for all 29 patients in Arm A (90Y-clivatuzumab
tetraxetan combined with low-dose gemcitabine) and all 29 patients in
Arm B (90Y-clivatuzumab tetraxetan alone).HAHA-positive after their ﬁrst (N = 3) or second
(N = 2) cycle, developing maximum titres of 135–
21,611 ng/mL. These were isolated laboratory ﬁndings
without event and of uncertain clinical signiﬁcance.4. Discussion
Patients with metastatic pancreatic cancer who seek
additional treatment after two prior treatment regimens
represent a select group of all patients with metastatic
occurrence of this disease, since only a small minority
of such patients currently receives further treatment
[31]. Nonetheless, in this trial, 58 patients with meta-
static pancreatic cancer and three median (2–7) prior
chemotherapies were enrolled within 8 months. The
rapidity of accrual reﬂects both the demand and the
unmet need for treatment options beyond the second
line as well as demonstrating the feasibility of
conducting trials in this setting. The fact that all
patients had received gemcitabine-containing
regimens (21% with nab-paclitaxel), and 97% had
received ﬂuoropyrimidine-containing regimens (50%Table 4
Dependence of overall survival (OS) on treatment and patient factors.
N Median (range), months
Treatment
Arm A, Overall 29 2.7 (0.4–23.9)
Single cycle 17 1.9 (0.4–11.0)
Multiple cycles 12 7.9 (3.9–23.9)
Arm B, Overall 29 2.6 (0.7–9.4)
Single cycle 18 1.7 (0.7–4.1)
Multiple cycles 11 3.4 (1.7–9.4)
Patient factors
Karnofsky performance status
90–100 24 4.0 (0.4–23.5)
70–80 34 2.0 (0.7–23.9)
Number of prior systemic treatments
2 19 2.9 (0.4 –23.9)
3 18 3.1 (0.9–23.5)
>3 21 2.4 (0.7–17.5)
Sum of index lesions (cm)
1.2–8.1 29 2.9 (0.7–23.5)
8.3–22.2 29 2.6 (0.4–23.9)
Serum CA19-9 (U/mL)
61257 29 3.9 (0.4–23.9)
>1257 28a 2.1 (0.7–8.4)
a Baseline CA19–9 unavailable in one patient.
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tance of developing additional treatments for pancreatic
cancer.
There were no infusion reactions and, as expected,
cytopaenias (predominantly thrombocytopenia) were
the only signiﬁcant toxicities. Even in this population,
these were mostly transient and reversible events, with
infrequent haematologic support required, and the few
infections or major bleeding events that occurred could
be attributed to complications of underlying disease.
Coagulopathy and thromboembolic events are known
risks in advanced pancreatic cancer with 10–20% inci-
dence rates reported in some studies [32], and while
treatment-related myelosuppression may have exacer-
bated the two cases of consumptive coagulopathy that
occurred, there is little evidence that treatment was
involved in the two cerebrovascular accidents that
occurred. Most other AEs were mild-moderate constitu-
tional and gastrointestinal events also expected in
advanced pancreatic cancer, and comparison of events
between treatment arms showed no substantial diﬀer-
ences. Although more limited than previously seen with
90Y-clivatuzumab tetraxetan in less heavily treated
patients [18,25], tumour response assessed by CT imag-
ing or CA19-9 levels still showed that our treatment is
active in this study, and the improvement of survival
with better responses and patient risk factors also sup-
ported the consistency of therapeutic results in this
advanced population. Thus, this combination approach
appears to be an acceptable regimen in this advanced
population.
Although median survival was only 2.7 months over-
all, survival progressively improved with time for
patients receiving low-dose gemcitabine (48% versus
35% alive at 3 months, 35% versus 10% at 6 months,
21% versus 3% at 9 months and 10% versus 0% at
1 year). For patients receiving only one cycle, there
was little diﬀerence between treatment arms, but with
multiple cycles median OS increased for the group
receiving gemcitabine (3.4 versus 7.9 months), including
three patients surviving >1 year. Imbalances of age,
KPS, serum CA19.9 levels, prior pancreatectomy and
exposure to FOLFIRINOX seen in Table 1 might mean
that patients in Arm A were possibly ﬁtter or had better
biologic factors that could also contribute to the better
results seen for the group treated with gemcitabine. As
with any repeated therapy, patients with less aggressive
disease would also likely be expected to receive more
cycles and do better, and dropouts occurring for other
reasons could further complicate treatment interpreta-
tion. Since the percent of patients in each arm proceed-
ing to receive multiple cycles was balanced in our study,
combining low-dose gemcitabine with radioim-
munotherapy appears more likely to be the primary
explanation for the increased survival results seen in
Arm A. However, this study was powered usingprespeciﬁed criteria for treatment arm activity, not sur-
vival, and patients were alternated to the treatment arm
assignment by the Sponsor. The interpretation of sur-
vival results is thus limited by the small sample size
and imbalances between treatment arms of potential sig-
niﬁcance, and should be considered encouraging but
preliminary.
This trial demonstrated the feasibility of performing
clinical studies in metastatic pancreatic cancer patients
after P2 prior chemotherapy regimens (3rd line and
beyond). This is important, because the beneﬁts of cur-
rent second-line therapies appear modest, at the cost of
drug toxicity [6,8–10], and increased availability of new
combination regimens such as FOLFIRINOX and
Abraxane/gemcitabine may also inﬂuence patient’s abil-
ity to choose, tolerate or respond to further therapy.
Acknowledging the limitations of this study,
90Y-clivatuzumab tetraxetan combined with low-dose
gemcitabine may be useful in this diﬃcult-to-treat pop-
ulation, and a Phase III trial of this combination is
now underway in this setting. (ClinicalTrials.gov
Identiﬁer: NCT01956812.)
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